Logo

Biogen and Alkermes Report Results of Diroximel Fumarate in P-III EVOLVE-MS-2 Study for Multiple Sclerosis

Share this

Biogen and Alkermes Report Results of Diroximel Fumarate in P-III EVOLVE-MS-2 Study for Multiple Sclerosis

Shots:

  • The P-III EVOLVE-MS-2 study assessing the GI tolerability of Diroximel Fumarate (462mg- bid) vs Tecfidera (dimethyl fumarate- 240 mg- bid) in 506 patients with RRMS
  • The P-III EVOLVE-MS-2 study results demonstrated superiority in gastrointestinal (GI) tolerability with a symptom intensity score ≥2 on the IGISIS rating scale and low discontinuation rates of <1% due to GI adverse events
  • Diroximel fumarate is a fumarate therapy designed to convert to monomethyl fumarate in the body and is under the US FDA review with its expected PDUFA date in Q4’19. Post-FDA’s approval- Biogen plans to market diroximel fumarate under the name Vumerity

Click here to­ read full press release/ article

| Ref: Biogen | Image: Biogen


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions